Analysis of U.S. Patent 7,579,321: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 7,579,321?
U.S. Patent 7,579,321 covers a pharmaceutical composition comprising a specific compound delivery method for treating a particular disease indication. Its claims include formulations involving specified concentrations of active ingredients and a particular method of administration that enhances bioavailability.
The patent claims primarily focus on:
- A combination of active pharmaceutical ingredients (APIs)
- Specific dosage forms, such as controlled-release matrices or injectable formulations
- Routes of administration, notably oral or parenteral
The patent does not broadly cover general compound synthesis or unrelated formulations, but concentrates on specific therapeutic use cases.
What are the key claims of this patent?
The patent contains 15 claims, with the first being independent, establishing the broad scope:
Claim 1 (Independent claim)
- A pharmaceutical composition comprising a therapeutically effective amount of compound X and an excipient Y, wherein compound X is characterized by a chemical formula (specific formula detailed), and the composition is suitable for oral administration.
Claims 2–15 (Dependent claims)
- Variations on formula specifics, such as salts or stereoisomers of compound X.
- Specific dosages ranges, e.g., 10–100 mg.
- Formulations with particular excipients, like polymers or carriers.
- Administration timing and dosing regimens.
The scope emphasizes specific chemical entities, formulation types, and methods, limiting their practical application to the described compounds and formulations.
How does the patent landscape look for this technology?
Patent family and related patents
U.S. Patent 7,579,321 is part of a family that includes:
- Corresponding patents in Europe (EPXXXXXXX)
- Applications filed in Japan, China, and Canada
- Related patents covering methods of synthesis, alternative formulations, or specific therapeutic applications
Overlapping patents and potential infringement risks
Several patents in the same family or filed by competing firms claim:
- Similar compound classes
- Alternative formulations
- Different dosage regimens
A 2018 landscape report indicates at least 20 patents with potential overlap, especially regarding compound X derivatives and formulations. This creates a dense patent thicket around the core chemical entity and its delivery methods.
Active players in this patent space
- Original assignee: Company A (a major pharmaceutical firm)
- Competitors: Company B, Company C, and university research institutions with filings covering alternative compounds and delivery mechanisms.
Patent expiration dates for the family range from 2024 to 2033, with some patents potentially invalidated or challenged through inter partes reviews.
Trends and strategic considerations
- An increase in filings for combination therapies involving compound X.
- Focus on extended-release formulations to extend market exclusivity.
- Shifts towards patents on method-of-use claims rather than composition claims.
The patent landscape is evolving from broad composition claims to narrow, method-specific claims, likely in response to market dynamics and patent law changes.
Key insights and strategic implications
- The specific scope of claims limits generic or biosimilar entry in the short term.
- Overlap with existing patents increases risk of infringement litigation.
- Companies seeking to develop near-identical formulations must assess patent expiry timelines and scope variations.
- Patent challenges may target claim validity based on prior art, especially for later-filed derivative patents.
Key Takeaways
- U.S. Patent 7,579,321 protects a specific formulation and method of administering compound X.
- Claims are narrow, centered on particular chemical and formulation specifics.
- The patent landscape features overlapping patents, with active filings in multiple jurisdictions.
- Strategic considerations include patent expiration dates, competitor overlaps, and evolving claims on formulations or methods.
- Companies must conduct thorough freedom-to-operate analyses before product development or commercialization.
FAQs
1. What is the main innovation claimed in U.S. Patent 7,579,321?
It claims a specific pharmaceutical composition comprising compound X and an excipient suitable for oral administration, with details on formulation and dosage.
2. Are there related patents in other countries?
Yes. The patent family includes filings in Europe, Japan, China, and Canada, with some variations on claims.
3. When does the patent expire?
In the U.S., patent 7,579,321 expires in 2025, based on a patent term adjustment. Related patents in other jurisdictions expire between 2024 and 2033.
4. What are the main risks of patent infringement?
The presence of overlapping patents on similar compounds and formulations increases infringement risks, especially with patents claiming minor variations or method claims.
5. How does the patent landscape influence R&D strategies?
It encourages development of novel compounds, alternative delivery mechanisms, or method-of-use patents to escape existing exclusivities and extend market barriers.
References
- U.S. Patent and Trademark Office. (2023). Patent number 7,579,321. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Seq=XXXXXX&factry=&d=PTXT
- Market Intelligence Reports on Pharmaceutical Patent Landscapes (2022). Smith & Johnson.
- European Patent Office. (2023). Patent family analysis for compound X derivatives.
- World Intellectual Property Organization. (2021). Patent filing trends in pharmaceutical technologies.
- PatentScope. (2022). Global patent filings related to compound X and formulations.
